Hepatitis C virus non-structural NS3/4A fusion gene
Disclosed herein is the discovery of a novel hepatitis C virus (HCV) isolated from a human patient. Embodiments of the inevntion include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as, methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection.
1. A purified or isolated nucleic acid consisting of the sequence of SEQ. ID. NO.: 1 or the complement thereof.
2. A purified or isolated nucleic acid comprising at least 100 consecutive nucleotides of SEQ. ID. No. 1 or the complement thereof.
3. The purified or isolated nucleic acid of claim 2 , comprising at least 200 consecutive nucleotides of SEQ. ID. No. 1.
4. The purified or isolated nucleic acid of claim 2 , comprising at least 500 consecutive nucleotides of SEQ. ID. No. 1.
5. The purified or isolated nucleic acid of claim 2 , comprising at least 1000 consecutive nucleotides of SEQ. ID. No. 1.
6. A purified or isolated nucleic acid consisting essentially of SEQ. ID. NO.: 1.
7. A purified or isolated nucleic acid comprising a sequence of SEQ. ID. NO.: 2.
8. A vector comprising the nucleic acid of claim 1 .
9. An isolated cell comprising the nucleic acid of claim 1 .
10. An immunogenic composition comprising the nucleic acid of claim 1 .
11. The immunogenic composition of claim 10 , further comprising an adjuvant.
12. A purified or isolated nucleic acid comprising SEQ. ID. NO.: 1.
13. A vector comprising the nucleic acid of claim 2 .
14. An isolated cell comprising the nucleic acid of claim 2 .
15. A vector comprising the nucleic acid of claim 3 .
16. An isolated cell comprising the nucleic acid of claim 3 .
17. A vector comprising the nucleic acid of claim 4 .
18. An isolated cell comprising the nucleic acid of claim 4 .
19. A vector comprising the nucleic acid of claim 5 .
20. An isolated cell comprising the nucleic acid of claim 5 .
21. A vector comprising the nucleic acid of claim 6 .
22. An isolated cell comprising the nucleic acid of claim 6 .
23. A vector comprising the nucleic acid of claim 7 .
24. An isolated cell comprising the nucleic acid of claim 7 .
25. A composition comprising the nucleic acid of claim 1 .
26. A composition comprising the nucleic acid of claim 2 .
27. A composition comprising the nucleic acid of claim 3 .
28. A composition comprising the nucleic acid of claim 4 .
29. A composition comprising the nucleic acid of claim 5 .
30. A composition comprising the nucleic acid of claim 6 .
31. A composition comprising the nucleic acid of claim 7 .
32. The composition of claim 25 further comprising an adjuvant.
33. The composition of claim 26 further comprising an adjuvant.
34. The composition of claim 27 further comprising an adjuvant.
35. The composition of claim 28 further comprising an adjuvant.
36. The composition of claim 29 further comprising an adjuvant.
37. The composition of claim 30 further comprising an adjuvant.
38. The composition of claim 31 further comprising an adjuvant.
39. The composition of claim 25 further comprising ribavirin.
40. The composition of claim 26 further comprising ribavirin.
41. The composition of claim 27 further comprising ribavirin.
42. The composition of claim 28 further comprising ribavirin.
43. The composition of claim 29 further comprising ribavirin.
44. The composition of claim 30 further comprising ribavirin.
45. The composition of claim 31 further comprising ribavirin.
46. A vector comprising the nucleic acid of claim 12 .
47. An isolated cell comprising the nucleic acid of claim 12 .
48. A composition comprising the nucleic acid of claim 12 .
49. The composition of claim 48 further comprising an adjuvant.
50. The composition of claim 49 further comprising ribavirin.